Market revenue in 2022 | USD 6.9 million |
Market revenue in 2030 | USD 21.9 million |
Growth rate | 15.6% (CAGR from 2022 to 2030) |
Largest segment | Stem cells |
Fastest growing segment | Other Products |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stem cells, Other Products |
Key market players worldwide | Boehringer Ingelheim, Zoetis Inc Class A, Dechra Pharmaceuticals, Integra Lifesciences Holdings Corp, Ardent Health Services, Vetherapy, VET-STEM INC., Enso Discoveries, Animal Cell Therapies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to veterinary regenerative medicine market will help companies and investors design strategic landscapes.
Stem cells was the largest segment with a revenue share of 52.17% in 2022. Horizon Databook has segmented the Canada veterinary regenerative medicine market based on stem cells, other products covering the revenue growth of each sub-segment from 2018 to 2030.
Stem cell treatment introduces stem cells from the body into diseased/damaged tissues, such as an arthritic joint or a torn ligament in the knee. Regenerative medicine, a method that enables the body to repair and regenerate damaged tissues, is a term that is frequently used to describe the procedure. In addition, the existence of companies that provide regenerative medicines for animals contributes to the market expansion.
For instance, eQcell, Inc. is Canada's leading clinical-stage regenerative medicine company that treats ailments affecting domestic and equine animals worldwide but for which palliative or insufficiently effective current treatments are available.
Allogeneic equine cord blood stem cells and canine adipose-derived mesenchymal stromal cells were created by eQcell to offer veterinarians worldwide off-the-shelf therapeutics that are more effective and predictable than the existing, time-consuming, and expensive autologous stem cell treatments that expand, extract, and reinject a horse's cells.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada veterinary regenerative medicine market , including forecasts for subscribers. This country databook contains high-level insights into Canada veterinary regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account